-
Mashup Score: 2#ACR 2024 BEST Abstracts from Day 2 | RheumNow - 7 hour(s) ago
Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty.
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet
-
Mashup Score: 0ACR 2024 - Day 2 Report | RheumNow - 8 hour(s) ago
Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024.
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet-
#ACR24 - Day 2 Report Plenary sessions began the day, followed by thousands on the abstract floor. Here are a few of my favorite presentations from day 2 at ACR 2024. https://t.co/TEWW0mDyl8 https://t.co/mZuqayonPN
-
-
Mashup Score: 3Safety of a JAKi Across 15,000 Patient-Years of Data | RheumNow - 14 hour(s) agoSource: rheumnow.comCategories: General Medicine News, General HCPsTweet
-
🔍 Safety of a JAKi Across 15,000 Patient-Years of Data Now in the RheumNow poster hall: Safety outcomes with a JAKi from 11 Phase 3 trials in adult patients with RA, PsA, AS, and nr-axSpA. Sponsored by AbbVie US Medical Affairs. https://t.co/WsUihGQ5Rt https://t.co/CrZQTgA16l
-
-
Mashup Score: 8Say Goodbye to Methotrexate in PMR? | RheumNow - 17 hour(s) ago
For decades, glucocorticoids (GCs) have formed the backbone of polymyalgia rheumatica (PMR) management. Whilst previously there was a sense that a “low” GC dose with limited duration was used, we now appreciate just how heterogenous the disease course of PMR can be, with many patients experiencing frequent relapses and garnering a subsequent huge GC burden over a number of years. This is a cause of significant concern, especially in this older vulnerable cohort of patients.
Source: rheumnow.comCategories: General Medicine News, RheumatologyTweet-
Say Goodbye to Methotrexate in PMR? Despite mixed results on its clinical efficacy in three previous randomised controlled trials (RCTs)1-3, methotrexate is considered the most widely used GC sparing agent. #ACR24 https://t.co/Q5Sw9dvYqJ https://t.co/jvEmg6aPcq
-
-
Mashup Score: 19
Lupus nephritis is one of the most silent and severe manifestations of SLE. When not captured early, patients are at high risk of progressing to end-stage renal disease, which would require dialysis or transplantation. Renal biopsy remains the gold standard for diagnosis and disease classification. However, the procedure is invasive and very painful. Non-invasive measures are critical for early detection and continuous monitoring.
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet-
Beyond the Needle: Redefining the Assessment of Lupus Nephritis Lupus nephritis is one of the most silent and severe manifestations of systemic lupus erythematosus (SLE). https://t.co/fvGG0BZbOL #ACR24 https://t.co/wPXQz9Vese
-
-
Mashup Score: 4Home | RheumNow - 1 day(s) ago
Rheumnow.com is a news source dedicated to the field of Rheumatology. It is written by experts in the field, and written for Rheumatologists and individuals working in related fields. Rheumnow.com provides daily updates on the site and in your inbox when you are signed up for our newsletter.
Source: rheumnow.comCategories: General Medicine News, RheumatologyTweet-
Leaving Academia Dr. Jack Cush reviews the news and journal reports from the past week on https://t.co/V10S4oVFsv. This week we discuss hipsters undergoing hip replacement, pregnancy outcomes in RA and the future of academic clinicians. https://t.co/cuENQxlSOt https://t.co/olMihVm4bU
-
-
Mashup Score: 2Taking CAR-T for a Test Drive | RheumNow - 1 day(s) ago
When the ACR Convergence 2024 abstract site went live, the first query I typed into the search bar was, “CAR-T.” I consider myself a CAR-T skeptic and would be surprised if the magical results from this NEJM case series replicate at scale, but it seems likely that CAR-T will revolutionize the care for (some) patients with rheumatic diseases. What new data will be presented at ACR?
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet-
Taking CAR-T for a Test Drive What is CAR-T? How can you get a healthy dose of it at #ACR24? And what does it mean for the future? Read on to find out! https://t.co/TnNHzWQndp https://t.co/qWgwjiEdLF
-
-
Mashup Score: 2Are Emulation Trials a Fantasy? | RheumNow - 1 day(s) ago
Are emulation ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)?
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet-
Are Emulation Trials a Fantasy? Are these ‘trials’ helpful, despite the biases that occur with observational data, or do they truly mimic the results of randomized controlled trials (RCTs)? https://t.co/x6NogGQksW https://t.co/f8o8N55tlJ
-
-
Mashup Score: 0#ACR 2024 BEST Abstracts from Day 1 | RheumNow - 2 day(s) ago
The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day at ACR 2024 in Washington, DC. Here are some of the best abstracts from Saturday Nov. 16th. You can also spot these on Twitter by looking for the (#ACRbest) hashtag.
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet-
#ACR24 BEST Abstracts from Day 1 The RheumNow faculty have parked at the plenaries, trafficked the posters and have been finding the best the meeting offers on the first day. https://t.co/FHu616Jpyq https://t.co/oKuRcGRRAZ
-
-
Mashup Score: 0RIP to Glucocorticoids in GPA | RheumNow - 2 day(s) ago
For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA). The paradigm shifted with cyclophosphamide and then again with rituximab, and we used less steroids, but we still used lots. Avacopan teased the demise of steroids, but in the trial they, and now we, still use them. Glucocorticoids are our old trusty friend, our comfort blanket. But no more! Good riddance to the medication with the highest long-term adverse event burden that we use. Long-term glucocorticoids in GPA should now be a rarity. The reason for such exuberance is the TAPIR study presented by Dr. Peter Merkel at Saturday’s opening plenary session.
Source: rheumnow.comCategories: General Medicine News, General HCPsTweet-
RIP to Glucocorticoids in GPA For many years glucocorticoids were the mainstay of our treatment of granulomatosis with polyangiitis (GPA). https://t.co/WqpO6ACqtu https://t.co/vb8qx3uHA0
-
#ACR24 BEST Abstracts from Day 2 Here’s a collection of some of the best abstracts presented on day 2 of ACR 2024 as selected by the RheumNow faculty. https://t.co/9qiPhemEPl https://t.co/uGQEiCcfah